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The vascular wall, composed of adventi-
tia, smooth muscle cells, and an endothe-
lium, is no longer viewed as a static 
structure but rather as a highly mutable 
organ responsive to the local mechani-
cal, hemodynamic, and neurohumoral 
milieus. The vasculature, along with the 
heart, distributes nutrient blood flow 
throughout the body. Resistance in the 
microvasculature is critical to regula-
tion of arterial blood pressure; failure 
to appropriately modulate arterial tone 
leads to hypertension (HT). Disruption 
of the endothelium lining the vasculature 
induces luminal thrombosis. Inflamma-
tory processes in the vessel wall are the 
early harbingers of atherosclerosis. This 
brief review looks at the major drug 
classes that have directly targeted vascu-
lar wall processes to treat HT, thrombo-
sis, and atherosclerosis, with a focus on 
the future opportunities for research.
Antihypertensives
It is widely recognized that treating HT 
reduces the risk of stroke, coronary artery 
disease, heart failure, renal disease, and 
cardiovascular mortality. Several major 
classes of drugs are available to treat HT, 
including α-blockers, β-blockers, vasodi-
lators, calcium channel blockers, inhibi-
tors of the renin–angiotensin–aldosterone 
(RAA) axis, and diuretics. Diuretics, intro-
duced in the 1950s, were among the earliest 
classes of antihypertensives. Hydralazine, 
one of the earliest vasodilators, was also 
introduced in this era. Diuretics do not 
act directly on the vasculature but rather 
reduce extracellular volume. Follow-ons 
to diuretics were drugs that more specifi-
cally targeted the vessel wall. Numerous 
α- and β-blockers with varying degrees 
of receptor subtype selectivity altered the 
neurohumoral milieu in the vessel wall. 
Calcium channel blockers, another class 
of antihypertensives, act directly at the 
vascular smooth muscle cells to vasodi-
late. Blockade of the endogenous RAA 
pathway is the mechanism underlying 
several successful antihypertensive agents. 
There are drug classes that target differ-
ent points in the RAA pathway, but these 
agents provide similar therapeutic benefit 
regardless of mechanism. The most recent 
and least tested of these RAA drugs are 
renin inhibitors that block angiotensin 
generation by directly inhibiting the rate-
limiting enzyme in this pathway. Whether 
aliskiren, approved in the United States as 
an antihypertensive in 2007, provides any 
unique benefit compared with other RAA 
pathway drugs will be apparent only with 
further clinical experience.
The discovery and development of 
novel antihypertensives have been almost 
completely abandoned by the major phar-
maceutical companies, with the exception 
of Merck, which entered a major collabo-
ration with NicOx to develop nitric oxide 
pathway–based agents. Although several 
vasoactive pathways have been explored 
preclinically as potential approaches to 
HT treatment, the challenge of introduc-
ing a new agent in a field that is arguably 
well satisfied is daunting. Most major 
classes of antihypertensives have gone 
generic, raising the bar for new agents 
to deliver increased value to the payer as 
well as the patient. Although this is not 
required for regulatory approval, many 
companies consider matching the mor-
bidity and mortality (M&M) data from 
currently approved agents to be impor-
tant for the commercial success of new 
agents. The cost of conducting M&M tri-
als requires a large up-front investment 
that is not easily recouped.
Nonetheless, from a mechanistic per-
spective, there are two areas that could 
provide unique HT therapies or provide 
benefit in specific patient populations. 
Therapies that specifically target the 
endothelial cells lining the vasculature 
and contribute to regulation of tone are 
largely unexplored. PDE5 inhibitors, used 
to treat erectile dysfunction, are an exam-
ple of drugs that improve endothelial 
function. PDE5 inhibitors have demon-
strated antihypertensive efficacy in small 
phase II trials. PDE5 inhibition is but one 
of several ways to target the endothelium 
via nitric oxide pathways, endothelium-
derived hyperpolarizing factors, or vari-
ous prostanoid agents.
Another approach to modulating vascu-
lar tone involves modifying the extracel-
lular matrix that provides the viscoelastic 
properties of the vasculature. It has been 
postulated that isolated systolic HT in 
the elderly may be the result of changes 
in the quantity and type of collagen in the 
vessel wall. The formation of advanced 
glycosylation end products (AGEs) lead-
ing to collagen crosslinking has been 
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tein cholesterol (LDL-C), reduced high-
density lipoprotein cholesterol (HDL-C), 
cigarette smoking, hypertension, and dia-
betes. Hypercholesterolemia is one means 
of disrupting the intact vascular endothe-
lial barrier. Inflammatory macrophages 
and foam cells in the vessel wall are the 
early markers of atherosclerotic plaque 
formation. Atherosclerotic vascular dis-
ease progresses over many decades, but 
as these lesions grow, the likelihood of 
plaque rupture increases. Rupturing of an 
atherosclerotic plaque exposes circulating 
blood to subendothelial factors, trigger-
ing clot formation.
Recognition of hypercholesterolemia 
and the subsequent treatment of dys-
lipidemias have reduced CHD mor-
tality by as much as 30–40%. Lifestyle 
changes in diet and exercise are the first 
and critical step in any treatment of lipid 
disorders. The most effective and best-
tolerated dyslipidemia drugs are the 
3-hydroxy-3-methylglutaryl–coenzyme 
A reductase inhibitors, or statins, which 
lower LDL-C. Other drugs for treat-
ing dyslipidemias include cholesterol-
absorption inhibitors, bile acid resins, 
nicotinic acid, and fibric acid derivatives. 
Both statins and bile acid resins target 
LDL-C. Resins are used less frequently, 
primarily for statin-intolerant patients, 
but are less efficacious. Nicotinic acid 
has favorable effects on HDL-C and 
triglycerides in addition to LDL-C. 
Sustained-release formulations of niacin, 
which have successfully addressed the 
flushing liability, are important players 
in the treatment of low HDL-C. Fibric 
acid derivatives have a more variable 
therapeutic profile that is dependent on 
the patient population.
The combination of a cholesterol- 
absorption inhibitor and a statin is 
highly effective at lowering LDL-C. 
Interestingly, a large-scale M&M trial 
of ezetimibe and simvastatin failed to 
decrease CHD events as compared with 
equivalent LDL-C lowering with a sta-
tin alone. The results from the Ezetimibe 
and Simvastatin in Hypercholestero-
lemia Enhances Atherosclerosis Regres-
sion (ENHANCE) trial have confounded 
researchers. In addition to new statins 
and statin combinations, other LDL-
C-lowering agents explored over the 
are two examples of P2Y receptor antago-
nists with demonstrated clinical efficacy. 
Another antiplatelet mechanism works 
by blocking the platelet surface integrin 
receptor. The resultant drug class, glyco-
protein IIb/IIIa inhibitors exemplified 
by abciximab, has shown benefit in con-
junction with percutaneous angioplasty. 
However, the high cost, parenteral route 
of administration, short half-life, and 
bleeding risk limit use of IIb/IIIa inhibi-
tors to interventional procedures.
The greatest opportunity in the field 
of antithrombotics is development of an 
orally active agent with reduced bleed-
ing risk compared with state-of-the art 
interventions. Rather than targeting 
the platelet–vessel wall interaction, new 
agents under investigation seek to disrupt 
key zymogens in the coagulation cascade, 
such as factor Xa. Several factor Xa inhibi-
tors are at various stages of clinical testing. 
Another critical component of coagula-
tion is tissue factor (TF), expressed in the 
subendothelium. TF amplifies the coag-
ulation cascade roughly 30,000-fold and 
thus exponentially drives clot formation. 
An orally active TF inhibitor has long 
been sought as a potential therapeutic. 
In theory, a TF inhibitor could provide 
anticoagulation with reduced bleeding 
risk compared with other inhibitors of 
the coagulation cascade. Thus far, no one 
has successfully brought an orally active 
TF inhibitor into clinical development.
Genetics has framed our understand-
ing of thrombosis for centuries, as with, 
for example, the recognition of heritance 
patterns in hemophilia. Today we have the 
know-how to track several gene variations 
that impact hemostasis. More important, 
genotyping is now used to predict the 
effectiveness of agents such as coumadin 
and clopidogrel. The growth of person-
alized medicine will continue to provide 
physicians with the tools to match the 
drug to the patient.
Antiatherosclerotics
Despite several decades of targeted inter-
vention, coronary heart disease (CHD, 
atherosclerosis), cerebrovascular disease, 
and peripheral vascular disease account 
for the majority of M&M in the elderly in 
the United States. Risk factors for CHD 
include elevated low-density lipopro-
hypothesized to contribute to HT and 
vascular disease in diabetics. Although 
numerous approaches, including matrix 
metalloproteinase inhibitors, AGE inhibi-
tors, and AGE breakers, have been profiled 
preclinically, none has demonstrated clini-
cal proof of concept as a antihypertensive. 
As we gain a better understanding of the 
microstructure of the vasculature, includ-
ing a more complete view of the dynamic 
nature of extracellular matrix and cell 
matrix interactions, new insights that 
could lead to new therapies await us. We 
have only begun to understand the high 
degree of plasticity in the vessel wall.
Interestingly, HT is a recognized side 
effect of more than one class of thera-
peutics. For example, the growth factor 
kinase inhibitors used to treat cancers are 
uniformly associated with HT. The use of 
recombinant erythropoietin in chronic 
renal failure patients induces HT in more 
than 25%. A better understanding of the 
mechanisms responsible for elevating 
blood pressure with some of these agents 
may lead to novel strategies for treating 
HT. The status quo is that most hyper-
tensive patients take two or three anti-
hypertensive medications. The holy grail 
in this field remains a single agent that 
normalizes blood pressure regardless of 
the patient cohort.
Antiplatelet agents
It is the delicate balance between proco-
agulant and anticoagulant activities that 
ensures the fluidity essential to normal 
blood flow. Damage or disruption of the 
vascular endothelium exposes circulating 
platelets to subendothelium, triggering 
aggregation and formation of a hemostatic 
plug. As part of normal physiology, this 
stimulation of plasma coagulation factors 
allows generation of a fibrin clot, which 
reinforces the platelet plug. In pathologi-
cal situations, clot formation occludes the 
blood vessel, resulting in ischemia.
Aspirin is the most widely recog-
nized and used antiplatelet agent. By 
covalently acetylating cyclooxygenase, 
aspirin effectively blocks production of 
thromboxane A2 throughout the life of 
the exposed platelet. Platelets contain 
two P2Y receptors, P2Y1 and P2Y2; tar-
geting either or both can prevent platelet 
aggregation. Ticlopidine and clopidogrel 
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help us better understand and interrogate 
pathways involved in atherosclerosis.
At present, fewer than 2% of the 671 
clinical trials registered at http://www.
ClinicalTrials.gov under the category of 
atherosclerosis represent novel drug enti-
ties. Forty percent of that extremely small 
subset target either soluble or lipoprotein 
PLA2; other mechanisms include chem-
okine receptor 2 and rho kinase.
Future breakthroughs in the treatment 
of atherosclerosis are critically depend-
ent on better methodologies to image 
and temporally track changes in human 
vasculature over months and years as dis-
ease develops. Approval of a direct-acting 
antiatherosclerotic agent will require 
M&M trials, but companies currently lack 
an intermediate step, or proof-of-concept 
measure, to reduce the risk of the larger 
M&M investment.
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scientific investment in the fundamental 
biology of HDL is critical.
Although treatment of dyslipidemias 
has had an enormous impact on overall 
cardiovascular M&M, not every patient 
who meets current National Cholesterol 
Education Program guidelines for lipid 
management remains disease-free. For 
many years scientists have studied drug 
targets that directly alter atherosclerotic 
disease progression in the vessel wall. 
From agents to prevent vascular inflam-
mation to agents that modify vascular 
trafficking of adhesion molecules, the 
opportunity is vast. Selectins, integrins, 
T cells, inflammatory monocytes, 
matrix metalloproteinases, and a host 
of cytokines have been implicated in the 
evolution of an atherosclerotic plaque. 
The field is hampered by the lack of ani-
mal models that recapitulate the complex-
ity of human atherosclerotic disease and 
by our inability to fully elucidate early 
changes in the vascular wall in humans. 
Advances in the field of genomics should 
past decade include microsomal trig-
lyceride transfer protein inhibitors and 
acyl-coenzyme A cholesteryl acyltrans-
ferase inhibitors. The latter have largely 
been abandoned. Studies continue with 
microsomal triglyceride transfer protein 
inhibition, although at a slower pace and 
with great care, given the potential risk 
of hepatic steatosis.
In an effort to raise HDL-C, several 
companies have targeted cholesteryl ester 
transfer protein (CETP). In late 2006, 
phase III clinical trials with torcetrapib, 
the most advanced CETP inhibitor, were 
halted because of an imbalance in all-cause 
mortality. The cause of the increased risk 
with torcetrapib remains undetermined. 
Clinical trials with other CETP inhibitors 
have resumed, albeit cautiously. With the 
failure of torcetrapib, it is clear that any 
novel mechanism of HDL-C elevation 
will need to demonstrate M&M benefit. 
HDL-C elevation remains a tremendous 
opportunity for new therapeutics, but 
the cost of entry will be high. Continued 
